Feed aggregator

Eiger's HDV Program Sees Cirrhosis in Younger Patients

Biospace news - Tue, 06/28/2022 - 02:00
​​​​​​​The findings, presented during a poster session at the EASL 2022 International Liver Congress, revealed that of the 407 D-LIVR participants, nearly 30% developed liver cirrhosis.

Kezar Stock Soars on Positive Lupus Nephritis Data

Biospace news - Tue, 06/28/2022 - 02:00
Kezar Life Sciences stock rose 92% after it announced positive topline results from its Phase II clinical trial investigating the use of zetomipzomib for the treatment of Lupus Nephritis (LN).

Biotech Companies Team Up to Design New Proteins with ML

Biospace news - Tue, 06/28/2022 - 02:00
Arzeda, Cyrus Biotechnology and Outpace Bio, are teaming up to use machine learning and optimize protein folding and design efforts.

Dr. Pearl Huang Named CEO of Novartis-Backed Dunad Therapeutics (Updated)

Biospace news - Tue, 06/28/2022 - 02:00
Pearl Huang, Ph.D, has been appointed the CEO of U.K.-based Dunad Therapeutics, a Novartis-backed biopharmaceutical startup.

Exercise in a Pill: Key Molecules Identified that Decrease Hunger Post-Exercise

Biospace news - Tue, 06/28/2022 - 02:00
For the exercise-phobic, a pill that would create the benefits of exercise without the work has been a pipe dream. Today, such a pill – actually, an “anti-hunger molecule” – is a bit closer to reality.

Harvard Researchers Uncover Insight into T Cells and Autoimmune Disease

Biospace news - Tue, 06/28/2022 - 02:00
Researchers from Harvard Medical School have published data in Science Daily involving the role of T cells in autoimmune diseases.

New approach to treatment of deadly kidney cancer

World Pharma News - Mon, 06/27/2022 - 10:00
Researchers at Karolinska Institutet in Sweden have linked resistance to treatment for a deadly form of kidney cancer to low mitochondrial content in the cell. When the researchers increased the mitochondrial content with an inhibitor, the cancer cells responded to the treatment. Their findings, which are published in Nature Metabolism, offer hope for more targeted cancer drugs.

More Gene Therapy Trouble for Astellas as FDA Pauses Pompe Trial

Biospace news - Mon, 06/27/2022 - 02:00
The FDA has placed Astellas Pharma's Phase I/II FORTIS trial on clinical hold after one of its study participants experienced a serious adverse event.

Ipsen Snags Epizyme and Cancer Portfolio for a Cool $247M

Biospace news - Mon, 06/27/2022 - 02:00
Ipsen announced it is acquiring the company and its cancer drugs, including Tazverik, which were approved for two different indications by the FDA in 2020.

Otsuka, Lundbeck Tout Positive Phase III Results for Alzheimer's Drug

Biospace news - Mon, 06/27/2022 - 02:00
Otsuka Pharmaceutical and Lundbeck announced positive Phase III clinical trial results Monday regarding brexpiprazole (Rexulti) as a treatment for agitation in patients with Alzheimer’s dementia.

Second UTHealth Study Suggests Flu Vaccine Offers Protection Against Alzheimer’s

Biospace news - Mon, 06/27/2022 - 02:00
Collectively, the data set found that 5.1% of vaccinated patients went on to develop AD, while 8.5% of unvaccinated patients developed the disease.

Mask On: Researchers Engineer “Masked” IL-12 Treatment to Fight Cancer

Biospace news - Mon, 06/27/2022 - 02:00
Researchers and drug developers have searched for a way to deliver IL-12 to patients. Researchers at the University of Chicago’s Pritzker School of Molecular Engineering may have found one.

Embarking on New Chapter, Zymeworks Taps Paul Moore as CSO

Biospace news - Mon, 06/27/2022 - 02:00
Another C-suite change at Zymeworks was announced Monday, with the appointment of Paul Moore, Ph.D. as chief scientific officer.

Amidst Legal Battle, BMS' CAR-T Therapy Scores Second FDA Approval

Biospace news - Mon, 06/27/2022 - 02:00
BMS’ CAR-T therapy Breyanzi picked up a second approval from the FDA. The cancer drug was approved for the treatment of adult patients with large B-cell lymphoma.

COVID-19 Vaccine Leaders Make Progress on Omicron-Specific Boosters

Biospace news - Mon, 06/27/2022 - 02:00
The current vaccinations still offer significant protection against severe diseases. Meanwhile, vaccine companies are progressing in designing and testing Omicron-specific booster shots.

Ascletis, Takeda, Arrowhead & More Present New Findings at EASL Liver Conference

Biospace news - Mon, 06/27/2022 - 02:00
For the first time in two years, the European Association for the Study of the Liver’s International Liver Congress was back on-site with cutting-edge research in hepatology and other sectors.

Clinical Catch-Up: xBiotech, Exelixis, DermBiont Target Cancer

Biospace news - Mon, 06/27/2022 - 02:00
While it was a relatively quiet week for clinical trial announcements overall, BioSpace takes a look at some of the more intriguing ones.

Hiring in Life Sciences is Becoming More Difficult, Study Shows

Biospace news - Mon, 06/27/2022 - 02:00
A report by CBRE shows that finding life sciences research talent may prove extremely difficult for employers. However, there are steps you can take to find top talent for these roles.

Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron

World Pharma News - Sat, 06/25/2022 - 10:00
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive data evaluating the safety, tolerability, and immunogenicity of two Omicron-adapted COVID-19 vaccine candidates: one monovalent and the other bivalent, a combination of the Pfizer-BioNTech COVID-19 Vaccine and a vaccine candidate targeting the spike protein of the Omicron BA.1 variant of concern.

Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by researchers

World Pharma News - Fri, 06/24/2022 - 10:00
An oral antiviral drug that targets a key part of the respiratory syncytial virus (RSV) polymerase and inhibits the synthesis of viral genetic material has been identified, a finding that could provide an effective treatment against RSV disease, according to researchers in the Center for Translational Antiviral Research at Georgia State University.